MFT
VKTX icon

Moisand Fitzgerald Tamayo’s Viking Therapeutics VKTX Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13
Closed – – 888
2022
Q2 		$0 Sell
13
-13
-50% -$32 ﹤0.01% 683
2022
Q1 		$0 Buy
+26
New +$93 ﹤0.01% 660

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Moisand Fitzgerald Tamayo's VKTX Position: Q3 2022 in Review

Moisand Fitzgerald Tamayo sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 13 shares.

Moisand Fitzgerald Tamayo first reported a position in VKTX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

  • Moisand Fitzgerald Tamayo reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 13 Viking Therapeutics shares in Q3 2022.
  • Moisand Fitzgerald Tamayo first reported a position in Viking Therapeutics in Q1 2022 and held it in 2 quarters.
  • Moisand Fitzgerald Tamayo's Viking Therapeutics position peaked at $0 in Q2 2022.
  • 107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2022, filed 26 Oct 2022.